• LionBio to develop intranasal GLP-1

  US-based startup LionBio, which describes itself as “The Nasal Peptide Company,” has published a video announcing the company’s launch with $6 million in seed funding and nose-to-brain delivery technology developed at Columbia University developed by… [Read more . . .]

• Phillips Medisize acquires remaining portion of former Vectura site

  Phillips Medisize, which completed its acquisition of inhalation CDMO Vectura in 2025, has announced the acquisition of all remaining portions of the former Vectura site in Chippenham, UK. The acquisition of Vectura originally included only… [Read more . . .]

• Ethris says Phase 2a trial of ETH47 intranasal antiviral in asthma patients demonstrated safety and antiviral activity

  Ethris has announced topline data from a Phase 2a challenge study of ETH47 mRNA-based antiviral in adults with mild-to-moderate asthma. According to Ethris, the trial demonstrated that ETH47 “was safe, well tolerated and showed antiviral… [Read more . . .]

• Abera gets approval for Phase 1 trial of its Ab-01.12 intranasal pneumococcal vaccine

  The Dutch Central Committee on Research Involving Human Subjects has approved Abera Bioscience’s application for a Phase 1 clinical trial of its Ab-01.12 intranasal pneumococcal vaccine, the company said. According to Abera, the dose escalation… [Read more . . .]

• Kindeva hires Daniel Couto as Executive VP, Inhalation & Specialty Drug Delivery

  Drug delivery specialist CDMO Kindeva has announced the appointment of Daniel Couto as Executive VP, Inhalation & Specialty Drug Delivery. Couto was most recently COO at Vedanta Biosciences. His prior experience includes executive positions at Vedanta,… [Read more . . .]

• CHI’s Quattrii DPI selected for UCL inhaled biologics project

• 1nhaler raises additional £2.2 million for development of its single-dose salbutamol (albuterol) DPI

• Tiziana says Phase 2a trial of intranasal foralumab in patients with na-SPMS met its primary endpoints

• Merck initiates the Phase 3 ENHANCE-3 trial of Ohtuvarye ensifentrine inhalation suspension for the prevention of COPD exacerbations

• FDA clears IND for Phase 1 trial of United Therapeutics’ treprostinil / iloprost SMI

More news . . .